Othman Al-Sawaf, MD, of the University of Cologne discusses follow-up data from the phase 3 CLL14 trial suggesting venetoclax plus obinutuzumab to be an effective long-term treatment for chronic lymphocytic leukemia (CLL) patients ineligible for standard treatment. Dr. Al-Sawaf presented this data at ASH 2020.
CLL is a rare blood cancer resulting in a build-up of lymphocytes in bone marrow, lymph nodes, and blood. The disease is considered treatable, but relapse is very common. Furthermore, many CLL patients cannot withstand the intensive chemotherapy needed to bring them into complete remission.
As Dr. Al-Sawaf explains, the CLL14 study, which was published in the New England Journal of Medicine in 2019, showed that the combination of venetoclax and obinutuzumab was more effective than the combination of chlorambucil and obinutuzumab in CLL patients who were ineligible for chemotherapy treatment. At ASH 2020, Dr. Al-Sawaf presented follow-up data from the CLL14 study which show that venetoclax-obinutuzumab combination therapy continues to be effective as a long-term treatment. Dr. Al-Sawaf also discusses mathematical models using MDS values which indicate that long term prospects are most encouraging for patients who have undetectable MDS values after 6 cycles of venetoclax-obinutuzumab.
For more information about CLL and other rare cancers, visit checkrare.com/diseases/cancers/